Aton Ra Partners Bicycle Therapeutics PLC Transaction History
Aton Ra Partners
- $50.1 Million
- Q4 2023
A detailed history of Aton Ra Partners transactions in Bicycle Therapeutics PLC stock. As of the latest transaction made, Aton Ra Partners holds 10,435 shares of BCYC stock, worth $204,317. This represents 0.38% of its overall portfolio holdings.
Number of Shares
10,435
Previous 11,588
9.95%
Holding current value
$204,317
Previous $232,000
18.97%
% of portfolio
0.38%
Previous 0.49%
Shares
8 transactions
Others Institutions Holding BCYC
# of Institutions
99Shares Held
30.6MCall Options Held
85.5KPut Options Held
11.6K-
Baker Bros. Advisors LP New York, NY4.94MShares$96.8 Million1.56% of portfolio
-
Deep Track Capital, LP Greenwich, CT3.49MShares$68.3 Million2.87% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY3.25MShares$63.6 Million3.03% of portfolio
-
Armistice Capital, LLC New York, NY1.67MShares$32.7 Million0.57% of portfolio
-
Tybourne Capital Management (Hk) LTD Hong Kong, K31.55MShares$30.3 Million8.61% of portfolio
About BICYCLE THERAPEUTICS plc
- Ticker BCYC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 29,676,100
- Market Cap $581M
- Description
- Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The co...